Rice William G. 4

What Happened
William G. Rice, Aptose Biosciences’ Chair, President & CEO and a director, disposed of a total of 6,026,252 common-share equivalents on 2026-06-30. That total includes a cash disposition of 613,252 shares at US$1.72 each for proceeds of $1,054,793, plus the disposition/settlement of 5,413,000 shares derived from options/derivative positions (reported at $0.00 cash). These disposals were made “to the issuer” as part of a board-, shareholder- and court-approved business arrangement under which a Hammi Pharmaceuticals subsidiary acquired all outstanding Aptose shares at C$2.41 per share.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (appears timely).
• Cash sale: 613,252 shares at US$1.72 = $1,054,793. (Canadian price C$2.41 converted at C$1.40 = US$1.00 per filing.)
• Derivative/option-related dispositions: 5,413,000 shares reported at $0.00 (settled as part of the acquisition arrangement).
• Total reported disposed: 6,026,252 share equivalents.
• Post-transaction holdings: Not specified in the filing summary provided.
• Footnotes: F1—dispositions pursuant to the Hammi acquisition agreement; F2—CAD→USD conversion used; F3—original option vesting schedule noted.
• Remarks: Option amounts and exercise prices were subject to adjustments from prior reverse stock splits (1:30 on 2/26/25 and 1:15 on 6/6/2023).

Context
“Disposition to the issuer” here reflects settlement/cancellation of shares and option-derived interests as part of the takeover transaction, not an open-market sale for trading. The $0.00 entries for many line items indicate those derivative positions were converted or cancelled under the acquisition terms rather than producing separate cash proceeds to the insider. The filed price per share matches the acquisition consideration when converted from CAD.